Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2008140586) MODULATION OF RHAMM (CD168) FOR SELECTIVE ADIPOSE TISSUE DEVELOPMENT
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

What is claimed is:
1. A method of for selectively enhancing subcutaneous adipose tissue development in a subject, the method comprising: providing an anti-Rhamm compound that blocks Rhamm function, administering said compound to a pre-selected subcutaneous are in a subject, whereby adipocyte formation occurs in dermal fibroblasts and volume is added in said selected subcutaneous area in the subject.

2. The method of claim 1 wherein the compound is an antibody that specifically binds Rhamm, soluble recombinant Rhamm protein fragments and peptide mimetics.

3. The method of claim 2 wherein the compound is a Rhamm peptide mimetic.

4. The method of claim 3 wherein the Rhamm peptide mimetic is substantially homologous to SEQ ID No:5.

5. The method of claim 5 wherein the subject is a human patient.

6. The method of claim 1 wherein the blocked Rhamm function is binding to CD44.

7. A method for selectively inhibiting visceral adipose tissue formation in a subject, the method comprising: providing an anti-Rhamm compound that blocks Rhamm function, administering to the subject an effective amount of said anti-Rhamm compound to block Rhamm function, thereby selectively inhibiting visceral adipose tissue formation in the subject.

8. The method of claim 7 wherein the compound is selected from the group consisting of anti-Rhamm antibodies, soluble recombinant Rhamm protein fragments and peptide mimetics.

9. The method of claim 7, wherein the subject is a mammal.

10. The method of claim 9, wherein the mammal is a human.

11. The method of claim 7, wherein the subject has been diagnosed with cardiovascular disease, diabetes or an obesity-related disease.

12. The method of claim 7, wherein the anti-Rhamm compound is an antibody, an aptamer, an antisense oligonucleotide, a peptide, or a peptidomimetic.

13. The method of claim 12, wherein the anti-Rhamm compound is an antibody.

14. The method of claim 12, wherein the anti-Rhamm compound is a peptide.

15. The method of claim 14, wherein the peptide having the sequence of SEQ ID No:5.

16. A method of modulating Rhamm to promote wound repair and contraction in an injured subject, comprising the steps of: providing a compound that enhances Rhamm function, administering said compound to the wounded area of a subject, whereby rate of wound contraction is increased.

17. A method of modulating Rhamm to promote muscle differentiation, comprising the steps of: providing a compound that enhances Rhamm function, administering said compound to a selected area of a subject, whereby muscle differentiation occurs more rapidly.

18. A method of modulating Rhamm to promote bone density, comprising the steps of: providing a compound that enhances Rhamm function, administering a compound that enhances Rhamm activity to a subject, whereby bone formation and density increases.

19. The methods of claim 16, 17 or 18 wherein the compound that enhances Rhamm activity is selected from the group consisting of Rhamm agonist antibodies, HA mimetics, or a Rhamm cDNA.

20. The method of claim 19, wherein the compound is an HA mimetic.

21. A composition for promoting wound repair in a wound but decreasing the formation of scarred tissue, said composition comprising an anti-Rhamm compound prepared in a topical cream or ointment.

22. A kit comprising an anti-Rhamm compound in freeze dried or liquid formulation in a predetermined concentration, a carrier for delivery of a therapeutic amount to a patient, and instructions for subcutaneous injection.